Immuron (IMRN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Sep 25, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMRN SEC filings page.
Immuron Limited (IMRN) reported $4.8M in revenue for fiscal year 2025, up 46.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Immuron’s reported balance sheet is lightly financed by liabilities, with most obligations current and substantial equity supporting the asset base.
The combination of$22.0M in assets,$2.4M in total liabilities, and a 0.1x liabilities-to-equity ratio indicates that the reported asset base is funded predominantly by equity rather than obligations. Because current assets were$20.4M against current liabilities of$2.2M , the 9.2x current ratio points to considerable short-term balance-sheet capacity.
The available FY2023 figures support a balance-sheet reading, not an operating-performance assessment: revenue, earnings, cash flow, and investment spending were not supplied. That means the data cannot establish whether the company’s activities are producing cash or requiring continued funding.
Equity of
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Immuron Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Immuron Limited, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Immuron Limited had 234M shares outstanding at the end of fiscal year 2025, against 228M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Immuron Limited scores 67/100 among other emerging companies.
Immuron Limited spent $2.4M on research and development in fiscal year 2025, which was 28.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Immuron Limited scores 61/100 among other emerging companies.
Immuron Limited reported revenue of $4.8M in fiscal year 2025, against $3.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Immuron Limited scores 85/100 among other emerging companies.
Immuron Limited's operations used $4.0M of cash in fiscal year 2025, against $3.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Immuron Limited scores 17/100 among other emerging companies.
Not available for Immuron Limited, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Immuron Limited scores -8.16, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $54.2M against total assets of $6.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Immuron Limited passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Immuron Limited reported a net loss of $3.4M while operations used $4.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Immuron Limited reported an operating loss of $3.5M against $5K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Immuron Limited generated $4.8M in revenue in fiscal year 2025. This represents an increase of 46.3% from the prior year.
Immuron Limited's EBITDA was -$3.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Immuron Limited reported a net loss of $3.4M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Immuron Limited earned -$1.49 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
Immuron Limited held $1.9M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Immuron Limited's gross margin was 65.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 2.7 percentage points from the prior year.
Immuron Limited's operating margin was -73.3% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Immuron Limited's net profit margin was -71.6% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Immuron Limited's ROE was -64.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.1 percentage points from the prior year.
Capital Allocation
Immuron Limited invested $2.4M in research and development in fiscal year 2025. This represents a decrease of 34.1% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
IMRN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8M+46.3% | $3.3M+172.2% | $1.2M+127.6% | $528K+383.5% | $109K-93.7% | $1.7M+22.9% | $1.4M+31.1% | $1.1M+0.6% | $1.1M+44.0% | $744K |
| Cost of Revenue | $1.7M+58.5% | $1.0M+216.7% | $330K+97.9% | $167K+335.9% | $38K-91.9% | $475K+1.5% | $468K+51.0% | $310K+19.6% | $259K+15.7% | $224K |
| Gross Profit | $3.1M+40.6% | $2.2M+155.4% | $872K+141.3% | $361K+409.2% | $71K-94.4% | $1.3M+4.6% | $1.2M+14.4% | $1.1M+29.7% | $813K+56.3% | $520K |
| R&D Expenses | $2.4M-34.1% | $3.6M+107.8% | $1.7M+280.3% | $454K-55.7% | $1.0M+26.1% | $812K+11.0% | $732K-56.2% | $1.7M-53.0% | $3.6M+32.0% | $2.7M |
| Operating Income | -$3.5Mn/m | -$3.9Mn/m | -$2.4Mn/m | -$2.0Mn/m | -$6.3Mn/m | -$2.0Mn/m | -$3.3Mn/m | -$2.3Mn/m | -$5.2M | N/A |
| EBITDA | -$3.5Mn/m | -$3.8Mn/m | -$2.3Mn/m | -$2.0Mn/m | -$6.2Mn/m | -$2.0M | N/A | N/A | N/A | N/A |
| Interest Expense | $5K-5.1% | $5K-21.3% | $6K+50.6% | $4K-58.6% | $10K-30.8% | $15K | N/A | $18K-74.0% | $69K-72.9% | $254K |
| Net Income | -$3.4Mn/m | -$4.6Mn/m | -$2.5Mn/m | -$2.0Mn/m | -$6.3Mn/m | -$2.0Mn/m | -$3.3Mn/m | -$2.3Mn/m | -$5.2Mn/m | -$5.3M |
| EPS (Basic) | -$1.49n/m | -$2.03n/m | -$1.11n/m | -$0.86n/m | -$2.84 | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | -$1.49n/m | -$2.03n/m | -$1.11n/m | -$0.86n/m | -$2.84 | N/A | N/A | N/A | N/A | N/A |
| Diluted Shares (Avg) | 231M+1.4% | 228M0.0% | 228M+0.1% | 228M | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: SG&A Expenses, Income Tax.
IMRN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.7M-35.9% | $10.4M-29.1% | $14.7M-14.6% | $17.2M-15.4% | $20.3M+374.3% | $4.3M-28.8% | $6.0M-12.3% | $6.8M+7.5% | $6.4M-3.0% | $6.6M |
| Current Assets | $6.6M-33.1% | $9.8M-27.7% | $13.6M-16.8% | $16.3M-15.3% | $19.3M+535.2% | $3.0M-35.1% | $4.7M-10.2% | $5.2M-17.8% | $6.3M | N/A |
| Cash & Equivalents | $1.9M-76.1% | $7.8M-31.9% | $11.4M-25.1% | $15.3M-18.7% | $18.8M+738.0% | $2.2M-37.6% | $3.6M+2.6% | $3.5M+14.1% | $3.1M+80.1% | $1.7M |
| Inventory | $1.2M+10.1% | $1.1M+89.0% | $560K+148.2% | $226K+2.8% | $219K-60.1% | $550K+44.1% | $382K+3.6% | $368K-79.5% | $1.8M | N/A |
| Accounts Receivable | $1.3M+36.6% | $926K+233.1% | $278K-39.2% | $458K+82.4% | $251K+11.1% | $226K-66.7% | $679K-45.5% | $1.2M-8.2% | $1.4M | N/A |
| Goodwill | N/A | N/A | N/A | $100K | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.4M-28.6% | $1.9M+20.0% | $1.6M+36.3% | $1.2M+33.5% | $868K+125.6% | $385K-54.6% | $848K+42.7% | $594K-54.8% | $1.3M-54.5% | $2.9M |
| Current Liabilities | $1.3M-28.3% | $1.8M+21.9% | $1.5M+42.5% | $1.0M+23.4% | $841K+136.2% | $356K-57.5% | $838K+41.0% | $594K-54.8% | $1.3M | N/A |
| Non-Current Liabilities | $62K-34.2% | $95K-6.8% | $101K-16.3% | $121K+346.5% | $27K-5.9% | $29K+174.7% | $10Kn/m | $0n/m | $0 | N/A |
| Total Equity | $5.3M-37.5% | $8.5M-35.1% | $13.1M-18.3% | $16.0M-17.6% | $19.4M+399.0% | $3.9M-24.5% | $5.2M-17.5% | $6.2M+23.7% | $5.0M+37.4% | $3.7M |
| Retained Earnings | -$54.2Mn/m | -$52.7Mn/m | -$48.0Mn/m | -$47.2Mn/m | -$49.4Mn/m | -$39.9Mn/m | -$40.1Mn/m | -$38.9Mn/m | -$38.0M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Long-Term Debt.
IMRN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0Mn/m | -$3.9Mn/m | -$1.7Mn/m | -$2.2Mn/m | -$3.1Mn/m | -$2.2Mn/m | -$1.3Mn/m | -$2.6Mn/m | -$5.3Mn/m | -$3.8M |
| Depreciation & Amortization | $33K+6.4% | $31K-5.3% | $32K+76.4% | $18K-43.9% | $33K+7.8% | $30K | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | $130-97.5% | $5K-25.7% | $7K+39.6% | $5K+734.5% | $596-58.5% | $1K-70.6% | $5K+11.6% | $4K+141.0% | $2K |
| Free Cash Flow | N/A | -$3.9Mn/m | -$1.7Mn/m | -$2.2Mn/m | -$3.1Mn/m | -$2.2Mn/m | -$1.3Mn/m | -$2.6Mn/m | -$5.3Mn/m | -$3.8M |
| Investing Cash Flow | -$1.9M-971.7% | $219Kn/m | -$1.7M-21650.7% | $8K+320.0% | $2Kn/m | -$596n/m | -$1Kn/m | -$4K-290.5% | $2Kn/m | -$2K |
| Financing Cash Flow | $131K+23619.6% | $554n/m | -$30Kn/m | -$29K-100.1% | $19.8M+2389.0% | $797K-45.0% | $1.5M-54.9% | $3.2M-51.3% | $6.6M+105.0% | $3.2M |
| Share Buybacks | N/A | N/A | $53K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid.
IMRN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.4%-2.7pp | 68.1%-4.5pp | 72.5%+4.1pp | 68.4%+3.4pp | 65.0%-7.7pp | 72.7%-12.7pp | 85.3%-12.4pp | 97.8%+21.9pp | 75.8%+5.9pp | 69.9% |
| Operating Margin | -73.3% | -118.3% | -197.8% | -375.0% | -5748.5% | -115.4% | -231.0% | -209.0% | -481.5% | N/A |
| Net Margin | -71.6% | -141.5% | -209.8% | -373.0% | -5751.6% | -116.2% | -231.0% | -210.6% | -487.3% | -706.1% |
| Return on Equity | -64.6%-10.1pp | -54.6%-35.3pp | -19.3%-7.0pp | -12.3%+20.1pp | -32.4%+19.5pp | -51.9%+11.5pp | -63.3%-27.0pp | -36.4%+67.1pp | -103.5%+39.6pp | -143.1% |
| Return on Assets | -51.5%-6.9pp | -44.6%-27.4pp | -17.2%-5.7pp | -11.5%+19.5pp | -31.0%+16.2pp | -47.2%+7.2pp | -54.4%-21.2pp | -33.2%+48.9pp | -82.1%-2.0pp | -80.1% |
| Current Ratio | 5.09-0.4x | 5.46-3.7x | 9.20-6.6x | 15.75-7.2x | 22.96+14.4x | 8.54+2.9x | 5.59-3.2x | 8.78+3.9x | 4.83 | N/A |
| Liabilities-to-Equity | 0.260.0x | 0.22+0.1x | 0.120.0x | 0.070.0x | 0.04-0.1x | 0.10-0.1x | 0.16+0.1x | 0.10-0.2x | 0.26-0.5x | 0.79 |
| Asset Turnover | 0.72+0.4x | 0.32+0.2x | 0.08+0.1x | 0.030.0x | 0.01-0.4x | 0.41+0.2x | 0.24+0.1x | 0.160.0x | 0.17+0.1x | 0.11 |
| FCF Margin | N/A | -119.9% | -144.2% | -412.7% | -2802.5% | -125.0% | -89.3% | -241.0% | -497.6% | -515.5% |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Immuron Limited IMRN | FY2025 | $4.8M | -$3.4M | -71.6% | $7.4M | 58/100 |
| XTL Biopharmaceuticals Ltd. XTLB | FY2025 | $451K | N/A | N/A | $4.3M | — |
| Phio Pharmaceuticals Corp. PHIO | FY2025 | N/A | -$8.7M | N/A | $10.0M | — |
Where Immuron Limited Ranks
Frequently Asked Questions
What is Immuron Limited's annual revenue?
Immuron Limited (IMRN) reported $4.8M in total revenue for fiscal year 2025. This represents a 46.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Immuron Limited's revenue growing?
Immuron Limited (IMRN) revenue grew by 46.3% year-over-year, from $3.3M to $4.8M in fiscal year 2025.
Is Immuron Limited profitable?
No, Immuron Limited (IMRN) reported a net loss of $3.4M in fiscal year 2025, with a net profit margin of -71.6%.
What is Immuron Limited's EBITDA?
Immuron Limited (IMRN) had EBITDA of -$3.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Immuron Limited's gross margin?
Immuron Limited (IMRN) had a gross margin of 65.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Immuron Limited's operating margin?
Immuron Limited (IMRN) had an operating margin of -73.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Immuron Limited's net profit margin?
Immuron Limited (IMRN) had a net profit margin of -71.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Immuron Limited's return on equity (ROE)?
Immuron Limited (IMRN) has a return on equity of -64.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Immuron Limited's operating cash flow?
Immuron Limited (IMRN) recorded an outflow of $4.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Immuron Limited's total assets?
Immuron Limited (IMRN) had $6.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Immuron Limited spend on research and development?
Immuron Limited (IMRN) invested $2.4M in research and development during fiscal year 2025.
What is Immuron Limited's current ratio?
Immuron Limited (IMRN) had a current ratio of 5.09 as of fiscal year 2025, which is generally considered healthy.
What is Immuron Limited's liabilities-to-equity ratio?
Immuron Limited (IMRN) had a liabilities-to-equity ratio of 0.26 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Immuron Limited's return on assets (ROA)?
Immuron Limited (IMRN) had a return on assets of -51.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immuron Limited's P/E ratio?
Immuron Limited (IMRN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.4M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Immuron Limited's price-to-sales ratio?
Immuron Limited (IMRN) trades at 1.6x sales, its market capitalization divided by $4.8M revenue, FY2025. The market capitalization is $7.4M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Immuron Limited's Altman Z-Score?
Immuron Limited (IMRN) has an Altman Z-Score of -8.16, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Immuron Limited's Piotroski F-Score?
Immuron Limited (IMRN) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immuron Limited's earnings high quality?
Immuron Limited (IMRN) reported a net loss of $3.4M while operations used $4.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Immuron Limited cover its interest payments?
Immuron Limited (IMRN) reported an operating loss of $3.5M against $5K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Immuron Limited?
Immuron Limited (IMRN) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Immuron Limited it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.